S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
NASDAQ:SMMT

Summit Therapeutics (SMMT) Stock Price, News & Analysis

$4.30
+0.19 (+4.62%)
(As of 02/22/2024 ET)
Today's Range
$3.95
$4.36
50-Day Range
$2.37
$5.07
52-Week Range
$1.25
$5.14
Volume
2.02 million shs
Average Volume
2.22 million shs
Market Capitalization
$3.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Summit Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
1.61% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.54mentions of Summit Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Acquiring Shares
$54,618 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.40 out of 5 stars

Medical Sector

882nd out of 934 stocks

Pharmaceutical Preparations Industry

400th out of 422 stocks


SMMT stock logo

About Summit Therapeutics Stock (NASDAQ:SMMT)

Summit Therapeutics Inc., a biopharmaceutical company, research and develops primarily oncology therapies in the United States, and the United Kingdom. The company's product pipeline includes SMT-738, a novel class of precision antibiotics for treatment which is in preclinical stage for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. for research and develop Ivonescimab (AK112) and SMT112, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis. The company was founded in 2003 and is headquartered in Cambridge, Massachusetts.

SMMT Stock Price History

SMMT Stock News Headlines

Summit Therapeutics plc (SMMT)
Q4 2023 Summit Therapeutics Inc Earnings Call
Clear Buy, Sell, or Hold Recommendation on any Stock, FREE
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Summit Therapeutics (NASDAQ:SMMT) Hits New 52-Week High at $4.87
SMMT Mar 2024 4.000 put
SMMT Apr 2024 3.000 call
Summit Therapeutics: Not For Retail Investors
See More Headlines
Receive SMMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
2/22/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SMMT
Employees
76
Year Founded
N/A

Profitability

Net Income
$-78,780,000.00
Pretax Margin
-271,685.00%

Debt

Sales & Book Value

Annual Sales
$700,000.00
Book Value
$0.60 per share

Miscellaneous

Free Float
114,237,000
Market Cap
$3.01 billion
Optionable
Optionable
Beta
-1.16
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Robert W. DugganMr. Robert W. Duggan (Age 79)
    Co-CEO & Executive Chairman
  • Dr. Mahkam Zanganeh D.D.S. (Age 54)
    M.B.A., Co-CEO, President & Director
    Comp: $934.85k
  • Mr. Ankur DhingraMr. Ankur Dhingra (Age 47)
    Chief Financial Officer
    Comp: $668.39k
  • Mr. Manmeet Singh Soni (Age 46)
    COO & Director
  • Dr. Urte Gayko Ph.D. (Age 53)
    Chief Regulatory, Quality & Pharmacovigilance Officer?
  • Prof. Dame Kay Davies DBE (Age 73)
    FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
  • Ms. Abby Guzman Murphy
    Head of Human Resources
  • Ms. Divya Chari (Age 56)
    Head of Global Clinical Operations
  • Mr. Dave Gancarz
    Chief Business & Strategy Officer?
  • Mr. Will Black
    Head of Information Technology?














SMMT Stock Analysis - Frequently Asked Questions

How have SMMT shares performed in 2024?

Summit Therapeutics' stock was trading at $2.61 at the beginning of 2024. Since then, SMMT stock has increased by 64.8% and is now trading at $4.30.
View the best growth stocks for 2024 here
.

When is Summit Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SMMT earnings forecast
.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) issued its earnings results on Monday, November, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.09. The company had revenue of $6.12 million for the quarter.

What ETFs hold Summit Therapeutics' stock?

ETFs with the largest weight of Summit Therapeutics (NASDAQ:SMMT) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of Summit Therapeutics own?
When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

Who are Summit Therapeutics' major shareholders?

Summit Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (1.00%), Northern Trust Corp (0.16%), Charles Schwab Investment Management Inc. (0.14%), Steward Partners Investment Advisory LLC (0.09%), Nuveen Asset Management LLC (0.08%) and Barclays PLC (0.05%). Insiders that own company stock include Ankur Dhingra, Mahkam Zanganeh, Maky Zanganeh, Manmeet Singh Soni and Robert W Duggan.
View institutional ownership trends
.

How do I buy shares of Summit Therapeutics?

Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SMMT) was last updated on 2/23/2024 by MarketBeat.com Staff